Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AWP Reform Remains Priority For CMS; Agency Will Act If No Bill By May

Executive Summary

The Centers for Medicare & Medicaid Services will address AWP reform administratively if Congress fails to act by May, CMS Administrator Tom Scully says

You may also be interested in...



Medicare AWP Reform: CMS Will Miss May Deadline, Part B Costs Up 35%

The Centers for Medicare & Medicaid Services will miss its self-imposed May deadline for proposing a plan to reform the AWP-based reimbursement system for Medicare Part B drugs

Medicare AWP Reform: CMS Will Miss May Deadline, Part B Costs Up 35%

The Centers for Medicare & Medicaid Services will miss its self-imposed May deadline for proposing a plan to reform the AWP-based reimbursement system for Medicare Part B drugs

House AWP reform proposal

Rep. Charles Norwood (R-Ga.) introduces AWP reform bill based on "average sales price" April 3. Medicare would pay "120% of the average sales price," defined as "weighted average of all final sales prices to all purchasers." HHS would have discretion to use "cumulative averages sales price" to reimburse for all FDA "A" rated therapeutic equivalents. HR 1622 is similar to legislation sponsored by Rep. Pete Stark (D-Calif.), including proposed $100,000 fine for manufacturers failing to provide HHS with pricing information (1"The Pink Sheet" Jan. 27, p. 9)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel